Acrylamide is a human neurotoxin classified as a probable carcinogen. It is present in heat-processed foods high in carbohydrate, such as snack foods, potato crisps, breads, cereal products, and coffee. Therefore acrylamide is considered a public health risk. Since April 2018, a new EU directive has entered into force, which urges food operators to monitor the presence of acrylamide in foodstuffs. However, existing acrylamide detection techniques rely on time-consuming, very expensive and complex assays that are only conducted to a few samples of products. Our INNOVATION provides a non-invasive, rapid, robust, accurate and 5x cheaper inspection system adapted for at-line and real-time monitoring.
It's is important to society because is A PUBLIC HEALTH PROBLEM INEFFICIENTLY CONTROLLED BY THE FOOD INDUSTRY. It was first detected in foods in April 2002 and prompted concerns about its toxic effects in humans. As a matter of fact, the Scientific Panel on Contaminants in the Food Chain (CONTAM) of the European Food Safety Authority (EFSA) confirms that acrylamide in food potentially increases the risk of developing cancer for consumers in all age groups . In the United States, acrylamide is also classified as an extremely hazardous substance.
The objetives were the Technical, Market and Financial Feasibility Study. The objectives defined for the Phase 1 have been successfully achieved. Centaurea has gained the relevant knowledge about the market of foodstuff affected by acrylamide and it has conducted a detailed competitor analysis targeting continental (Europe) and international areas. Together with the feedback of potential customers, our initial product idea has been slightly modified and the business plan has been duly updated. A suitable architecture is proposed and the necessary assessment of technical aspects has been completed. The feasibility of combining NIR sensor technology, the integration of app and cloud solutions, and the implementation of Software as a Service (SaaS) using data base processing strategies have been validated. Risks have been also evaluated and the overall conclusion is that AFREELAMIDE is achievable within a 2-year timeframe taking into account the previous experience of the company.